Quent Long Short Global Small Cap Fund LP Acquires New Position in Merck & Co., Inc. $MRK

Quent Long Short Global Small Cap Fund LP acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,157 shares of the company’s stock, valued at approximately $859,000.

A number of other institutional investors have also recently made changes to their positions in MRK. Darwin Wealth Management LLC grew its holdings in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after purchasing an additional 216 shares in the last quarter. Barnes Dennig Private Wealth Management LLC grew its holdings in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after purchasing an additional 266 shares in the last quarter. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. in the third quarter valued at approximately $31,000. Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. during the 3rd quarter worth $34,000. Finally, Dunhill Financial LLC grew its stake in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Guggenheim boosted their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a research note on Thursday, January 8th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $128.47.

Merck & Co., Inc. Trading Up 1.6%

NYSE:MRK opened at $114.68 on Friday. The stock has a 50-day simple moving average of $118.80 and a 200-day simple moving average of $106.58. The stock has a market cap of $283.25 billion, a P/E ratio of 15.75, a P/E/G ratio of 2.27 and a beta of 0.26. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 4.93 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were issued a $0.85 dividend. The ex-dividend date was Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Insiders Place Their Bets

In other news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer owned 90,192 shares in the company, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted Priority Review for two supplemental BLA filings for KEYTRUDA in combination regimens for muscle‑invasive bladder cancer — this could expand a high‑value label for KEYTRUDA if approved, supporting future revenue. Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer
• Positive Sentiment: Merck announced a multi‑year partnership with Google Cloud (up to $1B) to deploy agentic AI across R&D, manufacturing and commercial functions — a strategic investment that could boost long‑term productivity, R&D efficiency and digital transformation. Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
• Positive Sentiment: FDA approved IDVYNSO, a once‑daily two‑drug, non‑INSTI, tenofovir‑free HIV regimen — a new approved product can contribute incremental sales and diversify Merck’s commercial portfolio. Merck Weighs New HIV Approval Against Mixed Oncology Trial Results
• Neutral Sentiment: Reports say Merck and other drugmakers are eyeing a deal for Inhibrx’s experimental cancer drug tied to KEYTRUDA — strategic M&A/licensing interest is a potential longer‑term positive but remains speculative and valuation‑dependent. Exclusive: Merck, rivals eye deal in Inhibrx experimental cancer drug tied to Keytruda, sources say
• Neutral Sentiment: Market research notes expansion in the polycythemia vera field and lists Merck’s bomedemstat as one of several emerging entrants — a potential long‑term opportunity but competitive and years from wide commercial impact. Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036
• Negative Sentiment: Merck and partner Eisai reported a late‑stage Keytruda‑based triplet in first‑line advanced renal cell carcinoma failed to meet primary endpoints — this clinical setback has already pressured the stock and raises near‑term uncertainty around that program and investor confidence in certain oncology readouts. MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
• Negative Sentiment: Analysts expect Merck to report a year‑over‑year earnings decline and note Merck lacks the key factors typically associated with an earnings beat — weaker near‑term EPS guidance/expectations can cap upside and prompt short‑term selling. Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.